InMed Pharmaceuticals Inc (NASDAQ: INM) closed the day trading at $0.31 down -4.16% from the previous closing price of $0.32. On the day, 785397 shares were traded.
Ratios:
For a better understanding of INM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.58 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’24 when HULL ANDREW bought 37,500 shares for $0.39 per share. The transaction valued at 14,625 led to the insider holds 38,258 shares of the business.
ADAMS ERIC A bought 41,600 shares of INM for $14,922 on Feb 20 ’24. The President & CEO now owns 43,959 shares after completing the transaction at $0.36 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19 while its Price-to-Book (P/B) ratio in mrq is 0.14.
Stock Price History:
Over the past 52 weeks, INM has reached a high of $2.08, while it has fallen to a 52-week low of $0.29.
Shares Statistics:
A total of 3.33M shares are outstanding, with a floating share count of 3.28M. Insiders hold about 1.56% of the company’s shares, while institutions hold 24.17% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from — analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was –$. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with — analysts recommending between $0 and $0.
Revenue Estimates
1 analysts predict $1.49M in revenue for the current quarter. It ranges from a high estimate of $1.49M to a low estimate of $1.49M. As of the current estimate, InMed Pharmaceuticals Inc’s year-ago sales were $1.03M, an estimated increase of 44.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.79M, a decrease of -22.60% less than the figure of $44.10% in the same quarter last year. There is a high estimate of $1.79M for the next quarter, whereas the lowest estimate is $1.79M.
A total of 1 analysts have provided revenue estimates for INM’s current fiscal year. The highest revenue estimate was $5.42M, while the lowest revenue estimate was $5.42M, resulting in an average revenue estimate of $5.42M. In the same quarter a year ago, actual revenue was $4.14M, up 31.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.77M in the next fiscal year. The high estimate is $6.77M and the low estimate is $6.77M. The average revenue growth estimate for next year is up 24.90% from the average revenue estimate for this year.
